MK-8719

MK-8719 is a novel, potent, and selective small-molecule inhibitor of O-linked N-acetylglucosamine (O-GlcNAc)-ase (OGA), an enzyme that removes O-GlcNAc modifications from proteins. By inhibiting OGA, MK-8719 increases protein O-GlcNAcylation, which has been shown to reduce the formation of pathological tau aggregates and ameliorate neurodegeneration in preclinical models of tauopathies. The drug was developed through a collaboration between Alectos Therapeutics and Merck as a potential disease-modifying therapy for neurodegenerative diseases characterized by abnormal tau pathology, such as progressive supranuclear palsy (PSP) and Alzheimer's disease. It has demonstrated favorable pharmacokinetics and safety in Phase 1 clinical trials[1][2][4][6][7].

Other names

compound 42compound42compound-42